ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout

Kelonia’s in vivo CAR-T KLN-1010 showed 18-for-18 MRD negativity one month after treatment in relapsed/refractory multiple myeloma, with all assessable patients still negative at six months and the longest follow-up beyond 10 months. Safety also looked manageable, with 16 of 18 patients experiencing only grade 1-2 cytokine release syndrome and two cases of ICANS, supporting Lilly’s $3.2 billion acquisition rationale. The data strengthen the case for in vivo CAR-T as a potentially scalable approach and could lift sentiment across cell therapy and biotech platforms.

Analysis

This is less a single-program readout than a platform-validation event for in vivo cell therapy, and the biggest beneficiary is Lilly’s strategic credibility premium. The market should start pricing a higher probability that in vivo delivery becomes the lower-cost, faster-scalable route versus ex vivo CAR-T, which implies pressure on the valuation stack of legacy autologous cell-therapy infrastructure: manufacturing, vein-to-vein logistics, and the pick-and-shovel ecosystem built around individualized cell processing.

The second-order effect is that this data improves the odds of a broader M&A rerating for gene delivery and programmable RNA/vector platforms, because the bottleneck shifts from cell handling to targeting, dose control, and immunotoxicity management. If Lilly can convert this into clean phase 3 execution, it forces competitors working on allogeneic CAR-T to defend a harder proposition: they are no longer just competing with autologous complexity, but with a potentially off-the-shelf in vivo modality that may scale more like a drug than a biologic service line.

The main risk is not efficacy; it is reproducibility, dose-finding, and class-specific safety as enrollment expands beyond a highly selected early cohort. Expect the next 3-9 months to be the key window: any signal of diminishing MRD durability, higher-grade CRS/ICANS, or manufacturing variability would hit the entire in vivo thesis, not just this asset. The more subtle bearish setup is that enthusiasm may run ahead of clinical probability—platform stories often peak before the first real multicenter heterogeneity appears.

Consensus is likely underestimating how disruptive this is for allogeneic cell therapy developers. If in vivo works, the capital intensity and CMC complexity advantage may migrate away from the ex vivo space faster than many public comps reflect, creating a relative-value short against the crowded "next-gen cell therapy" basket.

Key Decisions for Investors

• Long LLY on 3-12 month horizon via call spreads or stock — the market may still be underpricing platform optionality from in vivo cell therapy; prefer structured upside because the rerating depends on continued clinical de-risking rather than near-term earnings.
• Short a basket of public allogeneic CAR-T names on a relative basis versus LLY — use a pair trade with defined beta hedging; thesis is that in vivo progress compresses the strategic value of ex vivo platform companies over the next 6-18 months.
• If available, accumulate exposure to enabling gene-delivery/vector infrastructure on weakness — the trade is on platform adoption, not one asset; use small sizing and expect volatility because sentiment will swing with each new dataset.
• Avoid chasing mid-cap biotech names with similar in vivo narratives into ASCO/ASH follow-through — the risk/reward is poor until multi-site durability and dose consistency are proven; fade rallies that are purely multiple expansion.
• Set a catalyst watch for the next dose-expansion and U.S. cohort updates over the next 1-2 quarters — any safety downgrade or weaker MRD durability should be treated as a fast exit signal for platform longs.